After being fired, I became the light of medicine

Chapter 186 The popular developer is officially on the market!

Foreign manufacturers led by Siemens and GE have long occupied 80% of China's CT market share, and it has never happened that domestic manufacturers can sell 60 CT machines at a time.

As soon as these words were spoken, the meeting of Siemens executives that had just begun became solemn.

Vice President Peter did not intend to stop, and after a brief pause, he continued:

"In addition to the fact that their first batch of sales reached nearly 60 units, the most troublesome thing is that... we have no countermeasures now, or we can't come up with any competing products."

"You can imagine, if you are the director of a hospital, would you rather purchase a CT machine that can perform traditional CT scans and identify the 'nature of lung nodules'? Or would you rather purchase a CT machine that can only perform traditional CT scans? The key is that the prices of these two CT machines are similar!"

"So, I can almost imagine that if we continue to develop like this, Elephant Medical will only need two or three years to take away most of our market share in China, and our profits in the Chinese market, which we have been operating for nearly 30 years, will plummet!"

“This is not alarmist.”

The serious Germans in the conference room fell silent, and everyone felt a strong sense of crisis.

"This won't work. We must find a way to deal with their threats."

About ten seconds later, a blond German executive in the silent conference room broke the silence and spoke.

"Yes, I agree that we must find a way to deal with it! The Chinese market is very important to us, and we can't let them grab our market share!"

"I agree."

After the blond executive finished speaking, two or three other executives in the conference room also expressed their opinions in a deep voice.

But at this moment, a deep voice suddenly sounded from among several high-level officials:

"I also agree that we must counterattack. We cannot lose the Chinese market!"

"But what countermeasures can we use at the moment?!"

"Qingshan Pharmaceutical has explicitly refused to cooperate with us. We simply cannot produce the same type of product as Elephant Medical that can identify lung nodules."

As soon as the words fell, the atmosphere in the conference room that had just been ignited suddenly fell silent again, and all the executives present couldn't help but frowned.

That's right.

In fact, Elephant Medical is not the key point. The technical level of Elephant Medical is just so-so. The most core and critical thing is Qingshan Pharmaceutical’s "Nano-nodule Contrast Agent"!
This is because their "nodule contrast agent" can identify whether lung nodules are benign or malignant, thereby producing a fluorescent reaction. Elephant Medical's CT machine only captures the fluorescence spectrum!
This time the silence lasted nearly a minute, and finally one of the executives spoke again:
"Everyone, I think the only way to deal with this is to develop a developer similar to Qingshan Pharmaceutical's 'Nano-nodule developer'."

"Only in this way, only with similar products and relying on our many years of brand recognition, can we truly counter Elephant Medical and compete with them!"

Develop Siemens’ own “nodule contrast agent”?

Everyone thought about it, and soon nodded.

but……

"I agree with this plan. After all, Qingshan Pharmaceutical has already developed the 'nano-nodule developer', and its technical patents and technical routes are all things we can learn from."

"only……"

"We have no experience in drug development. If we really want to develop a 'nodule developer' with similar functions, we may have to cooperate with other professional pharmaceutical companies."

It has to be said that the executive's speech really clarified everyone's thoughts.

If Siemens wants to maintain its existing brand competitiveness and compete with Elephant Medical, it must launch a CT machine with similar functions to Elephant Medical's "nodule imaging CT machine" as soon as possible.

It is obvious that Qingshan Pharmaceutical’s “nano-nodule developer” cannot be used, so it will cooperate with other pharmaceutical companies to develop drugs with similar functions!
This is the same as in other industries. Once a company develops a new feature that is widely acclaimed, the best approach is not to question it or remain indifferent.

Instead, they try their best to imitate the trend and produce similar functions and products as quickly as possible.

With the brand reputation that Siemens has accumulated in China over the years, as long as it launches products with similar functions, its market share will naturally be stabilized.

With a clear idea, the minds of several senior executives were completely opened:

“It is indeed a feasible approach for us to cooperate with professional pharmaceutical companies to develop drugs similar to ‘contrast agents’;

Also, since the contrast agent is targeted at lung nodules, it would be best to find a pharmaceutical company that develops lung drugs.”

"I know a little about this. The best lung cancer drug research and development company in Europe, and probably the world, is the British company AstraZeneca."

"They focus on the research and development of targeted drugs for lung cancer. The third-generation lung cancer targeted drug 'osimertinib' launched a few years ago has become the world's best and most profitable targeted lung cancer drug."

"I think we can contact AstraZeneca and start research and development of nodule contrast agents with them."

AstraZeneca?

The seven senior executives present all had some knowledge of the pharmaceutical company "AstraZeneca", and "AstraZeneca" was indeed a good partner.

Not only does it have strong professional capabilities, but its headquarters is also located in the UK, making communication very convenient.

Vice President Peter, the meeting host, nodded slightly and immediately began to look up more specific operating information of "AstraZeneca" on his computer.

But when he saw the main profit structure of AstraZeneca, Peter suddenly frowned.

After a moment, he coughed lightly, interrupting the heated discussion among the senior executives.

"Ladies and gentlemen, I think it's going to be very difficult for us to work with AstraZeneca."

"It's difficult?"

"Yes."

Peter turned the laptop on the conference table towards everyone and continued:
"This is the revenue share of AstraZeneca in last year's annual report. Their total drug sales reached US$440 billion last year, of which oncology drug revenue reached US$280 billion... accounting for as much as 63.6%."

"In other words, lung cancer drugs are their most important source of profit!"

"The 'nodule contrast agent' we want to develop is strictly speaking an early screening agent for lung cancer. Once it is widely popularized, it will inevitably reduce the incidence of lung cancer..."

Peter's words came to an abrupt end before he finished speaking.

But all the senior executives present understood the meaning of the second half.

The incidence of lung cancer has decreased, and the company that has been most affected is of course AstraZeneca, the world's best-selling and largest pharmaceutical company producing targeted lung cancer drugs!
Forget about the nonsense like “I wish that people in the world were healthy, and I would rather let the medicine gather dust on the shelf”. Modern drug research and development and sales have long become a capital business, but the threshold is just a little higher.

AstraZeneca certainly could not control Tsingshan Pharmaceutical when it was developing its own "nodule contrast agent", but if they were to cooperate in research and development, it would definitely be impossible for them to cooperate.

The senior executives in the conference room couldn't help but feel that the situation was a bit tricky. If the best lung cancer drug research and development company "AstraZeneca" couldn't succeed, were there any other suitable pharmaceutical companies?
Then several executives discussed several other pharmaceutical companies, but either they were not good at research and development in the field of lung cancer, or they had huge interests in lung cancer drugs like AstraZeneca.

The discussion suddenly reached a deadlock.

Fortunately, at this moment, the blond executive who spoke first suddenly raised his hand and said:

"If it's difficult to cooperate with pharmaceutical companies, I have another suggestion. We can cooperate with some well-known lung cancer 'biological laboratories'!"

"As far as I know, AstraZeneca's most popular third-generation targeted drug, Osimertinib, was also developed in collaboration with a biological laboratory."

"If I remember correctly, it should be a biological laboratory located in Norway that specializes in studying lung cancer viruses. It is called the 'Adrev' biological laboratory!" Norway, the "Adrev" biological laboratory that specializes in lung cancer viruses?

For the first time, the eyes of the executives lit up. The professionalism of this laboratory specializing in lung cancer viruses was beyond doubt.

And they do not have the conflicts of interest in targeted drugs like pharmaceutical companies do, so they are indeed a very good partner!
But just when all the executives were looking forward to getting more information about the Adleev Biological Laboratory, the blond man suddenly paused and spoke in a lower tone:
"However, the identity of the doctor in charge of this 'Adrev' biological laboratory is somewhat special."

"He is an American who graduated from Harvard University, the best university in the United States for viral biology."

“At the same time, he’s Jewish.”

Jewish?
Collaborate with Jewish Americans?
The discussion in the conference room came to an abrupt halt. Needless to say, Jews are very sensitive towards the Germans.

After a moment, everyone looked at Tobias, the president who had been silent in the conference room.

Tobias was also slightly surprised, but he didn't hesitate for long.

The best option is of course to cooperate with the British "AstraZeneca", but it is obviously impossible for the British at the moment.

However, other pharmaceutical companies cannot be trusted in terms of professionalism.

Compared with the Jews, the threat Siemens currently faces is more deadly.

About ten seconds later, he coughed lightly, glanced at the whole audience and said:

"Whatever the identity of the doctor behind the 'Adrev' biological laboratory is, let's get in touch with him first."

"No need to say anything else. I hope everyone understands that if we don't act quickly, two or three years later, do you really think that only the Chinese market will be affected?"

After the words were spoken, the conference room fell silent.

……

I have to say that Germany's Siemens Medical is indeed very efficient.

Under tremendous external pressure, they soon began preliminary cooperation negotiations with the Adrev Biological Laboratory.

Zhang Yang and Elephant Medical certainly didn’t know that due to the emergence of the “nodule contrast CT machine”, Siemens on the other side of the ocean had already begun planning to imitate the “nodule contrast agent”!

Of course, even if Zhang Yang knew this, he would not care too much. At this moment, he and the Third People's Hospital have already devoted themselves to the sprint for the last 100 subjects in the Phase III clinical trial of "Nano-nodule Contrast Agent".

Thanks to Director Zhou's recruitment of two experienced surgeons, 100 subjects soon began nodule surgery, and the pace of the Phase III clinical trial increased dramatically.

Ten days later, the surgeries for all 100 subjects were completed, which also meant the end of the Phase III clinical trial of the "Nano-nodule Contrast Agent".

A month later, the "nano-nodule contrast agent" developed by Tsingshan Pharmaceutical passed clinical trials and obtained production approval!
The next day, the official launch time of the "Nano-nodule developer" was determined. At the same time, the price of a single developer was also determined, 200 yuan per tube, one tube at a time.

In other words, if you are worried that your lung nodules are malignant, all patients only need to spend an additional 200 yuan to do a "nodule imaging CT" to find out whether their lung nodules are early lung cancer!
Professional media reported the news immediately!
[Good news, a must-read for all patients with lung nodules, good news for patients with lung nodules! ]

[The 'nodule contrast agent' developed by Qingshan Pharmaceutical will be officially launched soon. At that time, patients with lung nodules will no longer have to worry. They only need to take a 'nodule contrast CT scan' to determine the nature of the nodule! ]

[A hospital source revealed that the price of a 'nodule imaging CT scan' is about 700-900 yuan.]

[Currently, this drug has not been included in medical insurance reimbursement.]

The news quickly spread on the Internet and attracted the attention of countless netizens.

You should know that the number of patients with lung nodules in China has increased sharply in the past two years, and a large number of patients have been found to have many lung nodules through physical examinations at their companies.

It's fine if you have a good mentality and can follow the doctor's instructions for follow-up examinations. But if you are anxious, you can't eat or sleep well because of ground glass nodules, and there are many people who travel around the country to see countless doctors!
And now!
It’s finally on the market, and the price is not expensive, totally acceptable!

Netizens on the Internet are discussing it enthusiastically.

"700-900 yuan is totally acceptable! I originally thought it would be at least 1000-2000 per session! What a conscience!"

"Oh my god, it's finally going to be on the market. The price is not the most important thing. I can finally know whether my lung nodules are early lung cancer!"

"Yes, I saw that only the Third People's Hospital of Chengdu can perform 'nodule imaging CT' scans. When will other hospitals be able to open the service? When will my fifth-tier city have this function? I also want to go and get a CT scan!"

Not only are netizens discussing this online, but the major lung nodule patient groups are also extremely lively.

Compared with the netizens who like to watch the show, most of the patients in these patient groups and forums are in a similar situation to that of Mr. Zhang. They are all patients with nodules that are highly suspected of lung cancer, but are still struggling with whether to have surgery or not due to various reasons.

After all, the number of subjects recruited during the clinical trial of Tsingshan Pharmaceutical's "Nano-nodule Contrast Agent" was small, and the recruitment requirements were strict, so most people did not get a spot.

it's good now!

No need to grab!

"Dear patients, Qingshan Pharmaceutical's 'Nano-nodule Contrast Agent' has been launched on the market. Currently, only the Third People's Hospital of Chengdu can take 'Contrast CT' in the first place!"

"I just asked about the price. It's only 800 yuan per session. You can get an order by making an appointment with any doctor in the Department of Thoracic Surgery. Anyone who wants to have a photo taken should hurry up and make an appointment!"

“It is said that they take up to 500 pictures a day!”

"Okay, okay, I'll go register right away. I can't wait!"

"I am coming too!"

……

On the other side, a tertiary hospital in a fourth-tier city.

"My dear patient, it is really difficult to judge whether the lung nodules in your case are benign or malignant. If you rashly undergo surgery, the risk is very high and I am also worried that you will have the surgery in vain."

"Hey, doctor, thank you for considering me, but I'm really worried that it's lung cancer, and several doctors have said it might be lung cancer. After thinking about it, I decided to have surgery! If I make a mistake, it's a mistake."

The doctor suddenly smiled and then shook his head slowly.

"Maybe this was the only way before, but now medicine has made new progress."

"Have you been to Chengdu? It's about 300 kilometers away from here. Remember the address of the hospital. They can do a CT scan to detect lung nodules. If you go there, you will know whether it is malignant or benign!"

"what?!"

The patient was surprised and a glimmer of hope flashed in his eyes!
"Doctor, I know Rongcheng. Which hospital are you talking about? Huaxi?"

"No, it's the Third People's Hospital of Chengdu. Go there and make an appointment to get a CT scan!"

"Chengdu Third People's Hospital?"

"Thank you, thank you doctor!"

……

(End of this chapter)